To maximise value and transform patient outcomes
We have a portfolio of leading life science companies that are seeking to deliver transformational treatments to patients.
Founded by the Wellcome Trust in 2012, our Investment Manager, Syncona Investment Management Limited (SIML), is a leading life science investor with a strong track record of significant value creation from exits.
The team at SIML work in close partnership with world-class academic founders and experienced management teams, and have a broad range of scientific, operational, clinical, financial and commercial expertise. This enables them to effectively manage an increasingly mature portfolio, which is diversified across different stages of the development cycle and a range of therapeutic areas.
Our balance sheet underpins our strategy, enabling us to fund our portfolio companies to key value inflection points over the next three years.